



(19) REPUBLIKA HRVATSKA
DRŽAVNI ZAVOD ZA
INTELEKTUALNO VLASNIŠTVO

(10) Identifikator
dokumenta:



HR P20241273 T1

HR P20241273 T1

(12) **PRIJEVOD PATENTNIH ZAHTEJEVA
EUROPSKOG PATENTA**

(51) MKP:

C07D 471/04 (2006.01)
A61K 31/437 (2006.01)
A61K 31/496 (2006.01)
A61K 31/4545 (2006.01)
A61K 31/506 (2006.01)
A61P 31/00 (2006.01)
A61P 3/00 (2006.01)
A61P 25/00 (2006.01)
A61P 27/02 (2006.01)
A61P 11/00 (2006.01)

(46) Datum objave prijevoda patentnih zahtjeva: 06.12.2024.

(21) Broj predmeta: P20241273T

(22) Datum podnošenja: 25.02.2021.

(86) Broj međunarodne prijave: PCT/KR2021002364
Datum podnošenja međunarodne prijave: 25.02.2021.

(96) Broj europske prijave patenta: EP 21760609.4
Datum podnošenja europske prijave patenta: 25.02.2021.

(87) Broj međunarodne objave: WO 2021172887
Datum međunarodne objave: 02.09.2021.

(97) Broj objave europske prijave patenta: EP 4110781 A1
Datum objave europske prijave patenta: 04.01.2023.

(97) Broj objave europskog patenta: EP 4110781 B1
Datum objave europskog patenta: 31.07.2024.

(31) Broj prve prijave: 20200023251 (32) Datum podnošenja prve prijave: 25.02.2020. (33) Država ili organizacija podnošenja prve prijave: KR

(73) Nositelj patenta:

Chong Kun Dang Pharmaceutical Corp., 8, Chungjeong-ro, Seodaemun-gu, 03742 Seoul, KR

(72) Izumitelji:

Chang Kon Lee, 315-20, Dongbaekjukjeon-daero, Giheung-gu, Yongin-si, 16995 Gyeonggi-do, KR

Moo Sung Ko, 315-20, Dongbaekjukjeon-daero, Giheung-gu, Yongin-si, 16995 Gyeonggi-do, KR

Seok Hyoun Yun, 315-20, Dongbaekjukjeon-daero, Giheung-gu, Yongin-si, 16995 Gyeonggi-do, KR

Seo Young Lee, 315-20, Dongbaekjukjeon-daero, Giheung-gu, Yongin-si, 16995 Gyeonggi-do, KR

Hyunjin Michael Kim, 315-20, Dongbaekjukjeon-daero Giheung-gu, 16995 Yongin-si Gyeonggi-do, KR

(74) Zastupnik:

PRODUCTA d.o.o., 10000 Zagreb, HR

(54) Naziv izuma:


SPOJEVI DERIVATA 1,3,4-OKSADIAZOLA KAO INHIBITOR HISTON DEACETILAZE 6, TE FARMACEUTSKI PRIPRAVAK KOJI IH SADRŽI

HR P20241273 T1

PATENTNI ZAHTJEVI

1. Spoj derivata 1,3,4-oksadiazola predstavljen kemijskom formulom I ispod, njegov optički izomer, ili njegova farmaceutski prihvatljiva sol:

[Kemijska formula I]



u kemijskoj formuli I iznad,

L_1 , L_2 i L_3 su svaki neovisno $-(C_0-C_2\text{alkil})-$;


a , b i c su svaki neovisno N ili CR_4 , pri čemu a , b i c ne mogu istovremeno biti N, i R_4 je $-H$, $-X$ ili $-O(C_1-C_4\text{alkil})$;

Z je N, O, S, ili ništa (nula), pri čemu kada Z je ništa (nula), R_2 je također ništa (nula), i L_2 i L_3 su izravno povezani;

R_1 je $-CX_2H$ ili $-CX_3$;

R_2 je $-H$, $-(C_1-C_4\text{alkil})$, $-C(=O)-R^A$, $-C(=O)-OR^B$ ili $-C(=O)-NR^{CRD}$, pri čemu kada Z je O ili S, R_2 je ništa (nula);


R^A je $-(C_1-C_4\text{alkil})$, $-(C_1-C_4\text{alkil})-O-(C_1-C_4\text{alkil})$, $-(C_1-C_4\text{alkil})-C(=O)-O(C_1-C_4\text{alkil})$, $-aril$, $-heteroaril$, $-NR^{A1}R^{A2}$,



R^B do R^D su svaki neovisno $-H$, $-(C_1-C_4\text{alkil})$, $-(C_1-C_4\text{alkil})-O-(C_1-C_4\text{alkil})$, $-(C_1-C_4\text{alkil})-C(=O)-O(C_1-C_4\text{alkil})$, $-(C_3-C_7\text{cikloalkil})$, $-aril$ ili $-heteroaril$;

Y je N, CH, O ili $S(=O)_2$,

kada Y je N ili CH, R^{Y1} do R^{Y4} su svaki neovisno $-H$, $-X$, $-OH$, $-(C_1-C_4\text{alkil})$, $-(C_3-C_7\text{cikloalkil})$, $-(C_2-C_6\text{heterocikloalkil})$, $-(C_1-C_4\text{alkil})-O-(C_1-C_4\text{alkil})$, $-(C_1-C_4\text{alkil})-C(=O)-O(C_1-C_4\text{alkil})$, $-C(=O)-(C_1-C_4\text{alkil})$, $-C(=O)-O(C_1-C_4\text{alkil})$, $-C(=O)-NR^{A3}R^{A4}$, $-C(=O)-(C_3-C_7\text{cikloalkil})$, $-C(=O)-(C_2-C_6\text{heterocikloalkil})$, $-S(=O)_2-(C_1-C_4\text{alkil})$, $-aril$, $-(C_1-C_4\text{alkil})-aril$, $-heteroaril$, $-(C_1-C_4\text{alkil})-heteroaril$, aminska zaštitna skupina, ili



pri čemu najmanje jedan H iz $-(C_1-C_4\text{alkil})$, $-(C_3-C_7\text{cikloalkil})$, $-(C_1-C_4\text{alkil})-O-(C_1-C_4\text{alkil})$, $-(C_1-C_4\text{alkil})-C(=O)-O(C_1-C_4\text{alkil})$, $-C(=O)-(C_1-C_4\text{alkil})$, $-C(=O)-(C_3-C_7\text{cikloalkil})$, $-C(=O)-(C_2-C_6\text{heterocikloalkil})$ i $-S(=O)_2-(C_1-C_4\text{alkil})$ može biti supstituiran s $-X$ ili $-OH$; najmanje jedan H iz arila, $-(C_1-C_4\text{alkil})-arila$, $-heteroarila$ i $-(C_1-C_4\text{alkil})-heteroarila$ može biti supstituiran s $-(C_1-C_4\text{alkil})$, $-O-(C_1-C_4\text{alkil})$, $-X$, $-OH$ ili $-CF_3$; $-(C_2-C_6\text{heterocikloalkil})$, $-heteroaril$, $-(C_1-C_4\text{alkil})-heteroaril$ može sadržavati U prstenu atom N, O ili S; i W je NH, CH_2 ili O;

kada Y je O ili $S(=O)_2$, R^{Y1} do R^{Y4} su ništa (nula);

m i n su svaki neovisno cijeli broj 1, 2 ili 3;

R_a do R_d su svaki neovisno $-H$ ili $-(C_1-C_4\text{alkil})$;

R_3 je $-(C_3-C_7\text{cikloalkil})$, $-adamantil$, $-aril$ ili $-heteroaril$, pri čemu najmanje jedan $-H$ iz $-(C_3-C_7\text{cikloalkil})$, $-adamantila$, $-arila$ ili $-heteroarila$ može svaki neovisno biti supstituiran s $-X$, $-OH$, $-(C_1-C_4\text{alkil})$, $-O(C_1-C_4\text{alkil})$, $-(C=O)-(C_1-C_4\text{alkil})$, $-C(=O)-O(C_1-C_4\text{alkil})$, $-CF_3$, $-CF_2H$, $-OCF_3$, $-NR^{A5}R^{A6}$, $-S(=O)_2-(C_1-C_4\text{alkil})$, $-aril$ i $-heteroaril$;

R^{A1} do R^{A6} su svaki neovisno -H ili $-(C_1-C_4\text{alkil})$; i

X je F, Cl, Br ili I.

2. Spoj derivata 1,3,4-oksadiazola predstavljen kemijskom formulom I, njegov optički izomer, ili njegova farmaceutski prihvatljiva sol prema zahtjevu 1, pri čemu u kemijskoj formuli I iznad,

L_1 , L_2 i L_3 su svaki neovisno $-(C_0-C_1\text{alkil})$;


a, b i c su svaki neovisno N ili CR_4 , pri čemu a, b i c ne mogu istovremeno biti N, i R_4 je -H ili -X;

Z je N, O, ili ništa (nula), pri čemu kada Z je ništa (nula), R_2 je također ništa (nula), i L_2 i L_3 su izravno povezani;

R_1 je $-CX_2H$ ili $-CX_3$;


R_2 je -H, $-(C_1-C_4\text{alkil})$ ili $-C(=O)-R^A$, pri čemu kada Z je O, R_2 je ništa (nula);

R^A je $-NR^{A1}R^{A2}$,



Y je N, CH, O ili $S(=O)_2$;

kada Y je N ili CH, R^{Y1} do R^{Y4} su svaki neovisno -H, $-(C_1-C_4\text{alkil})$, $-(C_3-C_7\text{cikloalkil})$, $-(C_2-C_6\text{heterocikloalkil})$, $-C(=O)-(C_1-C_4\text{alkil})$, $-C(=O)-O(C_1-C_4\text{alkil})$, $-C(=O)-NR^{A3}R^{A4}$, $-C(=O)-(C_3-C_7\text{cikloalkil})$, $-C(=O)-(C_2-C_6\text{heterocikloalkil})$, $-S(=O)_2-(C_1-C_4\text{alkil})$, -aril, -heteroaril, ili



pri čemu najmanje jedan H iz $-(C_1-C_4\text{alkil})$, $-(C_3-C_7\text{cikloalkil})$, $-C(=O)-(C_1-C_4\text{alkil})$, $-C(=O)-(C_3-C_7\text{cikloalkil})$, $-C(=O)-(C_2-C_6\text{heterocikloalkil})$ i $-S(=O)_2-(C_1-C_4\text{alkil})$ može biti supstituiran s -X ili -OH; najmanje jedan H iz arila i heteroarila može biti supstituiran s $-(C_1-C_4\text{alkil})$, $-O-(C_1-C_4\text{alkil})$, -X, -OH ili $-CF_3$; $-(C_2-C_6\text{heterocikloalkil})$ ili -heteroaril može sadržavati u prstenu atome N, O ili S; i W je NH, CH_2 ili O;

kada Y je O ili $S(=O)_2$, R^{Y1} do R^{Y4} su ništa (nula);

m ili n je svaki neovisno cijeli broj 1 ili 2;

R_a do R_d su svaki neovisno -H ili $-(C_1-C_4\text{alkil})$;

R_3 je $-(C_3-C_7\text{cikloalkil})$, -adamantil, -aril ili -heteroaril, pri čemu najmanje jedan -H iz $-(C_3-C_7\text{cikloalkil})$, -adamantila, -arila ili -heteroarila može svaki neovisno biti supstituiran s -X, -OH, $-(C_1-C_4\text{alkil})$, $-O(C_1-C_4\text{alkil})$, $-C(=O)-(C_1-C_4\text{alkil})$, $-C(=O)-O(C_1-C_4\text{alkil})$, $-CF_3$, $-CF_2H$, $-OCF_3$, $-NR^{A5}R^{A6}$, $-S(=O)_2-(C_1-C_4\text{alkil})$, -aril, ili -heteroaril;

R^{A1} do R^{A6} su svaki neovisno -H ili $-(C_1-C_4\text{alkil})$; i

X je F, Cl ili Br.

3. Spoj derivata 1,3,4-oksadiazola predstavljen kemijskom formulom I, njegov optički izomer, ili njegova farmaceutski prihvatljiva sol prema zahtjevu 2, pri čemu u kemijskoj formuli I iznad,

L_1 i L_3 su svaki neovisno $-(C_0\text{alkil})$;

L_2 je $-(C_1\text{alkil})$;


a, b i c su CR_4 , pri čemu R_4 je -H ili -X;


Z je N, O, ili ništa (nula), pri čemu kada Z je ništa (nula), R_2 je također ništa (nula), i L_2 i L_3 su izravno povezani;

R_1 je $-CF_2H$ ili $-CF_3$;

R_2 je -H ili $-C(=O)-R^A$, pri čemu Z je O, R_2 je ništa (nula);


R^A je





Y je N;

R^{Y1} do R^{Y4} su svaki neovisno $-(C_1-C_4\text{alkil})$, $-(C_3-C_7\text{cikloalkil})$, $-(C_2-C_6\text{heterocikloalkil})$, $-C(=O)-(C_1-C_4\text{alkil})$, $-C(=O)-O(C_1-C_4\text{alkil})$, $-C(=O)-NR^{A3}R^{A4}$, $-C(=O)-(C_3-C_7\text{cikloalkil})$, $-C(=O)-(C_2-C_6\text{heterocikloalkil})$, $-S(=O)_2-(C_1-C_4\text{alkil})$, -heteroaril, ili



pri čemu najmanje jedan H iz $-(C_1-C_4\text{alkil})$, $-(C_3-C_7\text{cikloalkil})$, $-C(=O)-(C_1-C_4\text{alkil})$, $-C(=O)-(C_3-C_7\text{cikloalkil})$, $-C(=O)-(C_2-C_6\text{heterocikloalkil})$ i $-S(=O)_2-(C_1-C_4\text{alkil})$ može biti supstituiran s -X ili -OH; najmanje jedan H iz heteroarila može biti supstituiran s $-(C_1-C_4\text{alkil})$, $-O-(C_1-C_4\text{alkil})$, -X, -OH ili $-CF_3$; $-(C_2-C_6\text{heterocikloalkil})$ ili -heteroaril može sadržavati u prstenu atome N, O ili S; i W je CH_2 ili O;

m i n su svaki neovisno cijeli broj 1 ili 2;

R_a do R_d su svaki neovisno -H ili $-(C_1-C_4\text{alkil})$;

R_3 je $-(C_3-C_7\text{cikloalkil})$, -adamantil, -aril ili -heteroaril, pri čemu najmanje jedan -H iz $-(C_3-C_7\text{cikloalkil})$, -adamantila, -arila ili -heteroarila može svaki neovisno biti supstituiran s -X, $-(C_1-C_4\text{alkil})$, $-O(C_1-C_4\text{alkil})$, $-C(=O)-(C_1-C_4\text{alkil})$, $-CF_3$, ili $-S(=O)_2-(C_1-C_4\text{alkil})$;

R^{A1} do R^{A6} su svaki neovisno -H ili $-(C_1-C_4\text{alkil})$; i

X je F ili Cl.

4. Spoj derivata 1,3,4-oksadiazola predstavljen kemijskom formulom I, njegov optički izomer, ili njegova farmaceutski prihvatljiva sol prema zahtjevu 2, pri čemu u kemijskoj formuli I iznad,

L_1 , L_2 ili L_3 je svaki neovisno $-(C_0-C_1\text{alkil})$;


a, b i c su svaki neovisno N ili CR_4 , pri čemu a, b i c ne mogu istovremeno biti N, i R_4 je -H ili -X;

Z je N;

R_1 je $-CX_2H$ ili $-CX_3$;


R_2 je $-C(=O)-R^A$;

R^A je



Y je N, CH, O ili $S(=O)_2$;

kada Y je N ili CH, R^{Y1} i R^{Y3} su svaki neovisno -H, $-(C_1-C_4\text{alkil})$, $-(C_3-C_7\text{cikloalkil})$, $-(C_2-C_6\text{heterocikloalkil})$, $-C(=O)-(C_1-C_4\text{alkil})$, $-C(=O)-O(C_1-C_4\text{alkil})$, $-C(=O)-NR^{A3}R^{A4}$, $-C(=O)-(C_3-C_7\text{cikloalkil})$, $-C(=O)-(C_2-C_6\text{heterocikloalkil})$, $-S(=O)_2-(C_1-C_4\text{alkil})$, -aril, -heteroaril, ili



pri čemu najmanje jedan H iz $-(C_1-C_4\text{alkil})$, $-(C_3-C_7\text{cikloalkil})$, $-C(=O)-(C_1-C_4\text{alkil})$, $-C(=O)-(C_3-C_7\text{cikloalkil})$, $-C(=O)-(C_2-C_6\text{heterocikloalkil})$ i $-S(=O)_2-(C_1-C_4\text{alkil})$ može biti supstituiran s -X ili -OH; najmanje jedan H iz arila i heteroarila može biti supstituiran s $-(C_1-C_4\text{alkil})$, $-O-(C_1-C_4\text{alkil})$, -X, -OH ili $-CF_3$; $-(C_2-C_6\text{heterocikloalkil})$ ili -heteroaril može sadržavati u prstenu atome N, O ili S; i W je NH, CH_2 ili O;

kada Y je O ili $S(=O)_2$, R^{Y1} i R^{Y3} su ništa (nula);

m i n su svaki neovisno cijeli broj 1 ili 2;

R_a do R_d su svaki neovisno -H ili $-(C_1-C_4\text{alkil})$;

R_3 je $-(C_3-C_7\text{cikloalkil})$, -adamantil, -aril ili -heteroaril, pri čemu najmanje jedan -H iz $-(C_3-C_7\text{cikloalkil})$, -adamantila, -arila i -heteroarila može svaki neovisno biti supstituiran s -X, -OH, $-(C_1-C_4\text{alkil})$, $-O(C_1-C_4\text{alkil})$, $-(C=O)-(C_1-C_4\text{alkil})$, $-C(=O)-O(C_1-C_4\text{alkil})$, $-CF_3$, $-CF_2H$, $-OCF_3$, $-NR^{A5}R^{A6}$, $-S(=O)_2-(C_1-C_4\text{alkil})$, -aril, ili -heteroaril;

R^{A3} do R^{A6} su svaki neovisno -H ili $-(C_1-C_4\text{alkil})$; i

X je F, Cl ili Br.

5. Spoj derivata 1,3,4-oksadiazola predstavljen kemijskom formulom I, njegov optički izomer, ili njegova farmaceutski prihvatljiva sol prema zahtjevu 2, pri čemu u kemijskoj formuli I iznad,

L_1 , L_2 i L_3 su svaki neovisno $-(C_0-C_1\text{alkil})$;


a, b i c su svaki neovisno N ili CR_4 , pri čemu a, b i c ne mogu istovremeno biti N, i R_4 je -H ili -X;

Z je N;

R_1 je $-CX_2H$ ili $-CX_3$;


R_2 je $-C(=O)-R^A$;

R^A je $-NR^{A1}R^{A2}$,



Y je N, CH, O ili $S(=O)_2$;

kada Y je N ili CH, R^{Y2} i R^{Y4} su svaki neovisno -H, $-(C_1-C_4\text{alkil})$, $-(C_3-C_7\text{cikloalkil})$, $-(C_2-C_6\text{heterocikloalkil})$, $-C(=O)-(C_1-C_4\text{alkil})$, $-C(=O)-O(C_1-C_4\text{alkil})$, $-C(=O)-NR^{A3}R^{A4}$, $-C(=O)-(C_3-C_7\text{cikloalkil})$, $-C(=O)-(C_2-C_6\text{heterocikloalkil})$, $-S(=O)_2-(C_1-C_4\text{alkil})$, -aril, -heteroaril, ili



pri čemu najmanje jedan H iz $-(C_1-C_4\text{alkil})$, $-(C_3-C_7\text{cikloalkil})$, $-C(=O)-(C_1-C_4\text{alkil})$, $-C(=O)-(C_3-C_7\text{cikloalkil})$, $-C(=O)-(C_2-C_6\text{heterocikloalkil})$ i $-S(=O)_2-(C_1-C_4\text{alkil})$ može biti supstituiran s -X ili -OH; najmanje jedan H iz arila ili heteroarila može biti supstituiran s $-(C_1-C_4\text{alkil})$, $-O(C_1-C_4\text{alkil})$, -X, -OH ili $-CF_3$; $-(C_2-C_6\text{heterocikloalkil})$ ili -heteroaril može sadržavati u prstenu atome N, O ili S; i W je NH, CH_2 ili O;

kada Y je O ili $S(=O)_2$, R^{Y2} i R^{Y4} su ništa (nula);

m i n su svaki neovisno cijeli broj 1 ili 2;

R_a do R_d su svaki neovisno -H ili $-(C_1-C_4\text{alkil})$;

R_3 je $-(C_3-C_7\text{cikloalkil})$, -adamantil, -aril ili -heteroaril, pri čemu najmanje jedan -H iz $-(C_3-C_7\text{cikloalkil})$, -adamantila, -arila i -heteroarila može svaki neovisno biti supstituiran s -X, -OH, $-(C_1-C_4\text{alkil})$, $-O(C_1-C_4\text{alkil})$, $-(C=O)-(C_1-C_4\text{alkil})$, $-C(=O)-O(C_1-C_4\text{alkil})$, $-CF_3$, $-CF_2H$, $-OCF_3$, $-NR^{A5}R^{A6}$, $-S(=O)_2-(C_1-C_4\text{alkil})$, -aril, ili -heteroaril;

R^{A1} do R^{A6} su svaki neovisno -H ili $-(C_1-C_4\text{alkil})$; i

X je F, Cl ili Br.

6. Spoj derivata 1,3,4-oksadiazola predstavljen kemijskom formulom I, njegov optički izomer, ili njegova farmaceutski prihvatljiva sol prema zahtjevu 2, pri čemu u kemijskoj formuli I iznad,

L_1 , L_2 su L_3 su svaki neovisno $-(C_0-C_1\text{alkil})$;

a, b i c su svaki neovisno N ili CR_4 , pri čemu a, b i c ne mogu istovremeno biti N, i R_4 je -H ili -X;

Z je N, O, ili ništa (nula), pri čemu kada Z je ništa (nula), R_2 je također ništa (nula), i L_2 i L_3 su izravno povezani;

R_1 je $-CX_2H$ ili $-CX_3$;

R_2 je -H, $-(C_1-C_4\text{alkil})$, pri čemu kada Z je O, R_2 je ništa (nula);

























R_3 je $-(C_3-C_7\text{cikloalkil})$, -adamantil, -aril ili -heteroaril, pri čemu najmanje jedan -H iz $-(C_3-C_7\text{cikloalkil})$, -adamantila, -arila i -heteroarila može svaki neovisno biti supstituiran s -X, -OH, $-(C_1-C_4\text{alkil})$, $-O(C_1-C_4\text{alkil})$, $-(C=O)-(C_1-C_4\text{alkil})$, $-C(=O)-O(C_1-C_4\text{alkil})$, $-CF_3$, $-CF_2H$, $-OCF_3$, $-NR^{A5}R^{A6}$, $-S(=O)_2-(C_1-C_4\text{alkil})$, -arilom, ili -heteroarilom;





















R^{A5} i R^{A6} su svaki neovisno -H ili $-(C_1-C_4\text{alkil})$; i

X je F, Cl ili Br.

7. Spoj derivata 1,3,4-oksadiazola, njegov optički izomer ili njegova farmaceutski prihvatljiva sol prema zahtjevu 1, naznačen time što je bilo koji od spojeva navedenih u sljedećoj tablici:

Prim.	Spoj	Struktura	Prim.	Spoj	Struktura
1	3009		2	3585	

					
3	3586		4	3587	
5	3588		6	3589	
7	3590		8	3591	
9	3592		10	3593	
11	3594		12	3595	
13	3596		14	3668	
15	3669		16	3670	
17	3671		18	3672	
19	3673		20	3674	
21	3675		22	3676	
23	3677		24	3678	
25	3679		26	3719	
27	3720		28	3721	

















					
29	3722		30	3723	
31	3724		32	3725	
33	3782		34	3783	
35	3784		36	3785	
37	4033		38	4034	
39	4035		40	4036	
41	4037		42	4038	
43	4039		44	4040	
45	4041		46	4042	
47	4043		48	4044	

49	4045		50	4046	
51	4047		52	4048	
53	4049		54	4083	
55	4084		56	4085	
57	4086		58	4087	
59	4088		60	4089	
61	4090		62	4091	
63	4092		64	4093	

65	4094		66	4095	
67	4096		68	4097	
69	4098		70	4099	
71	4100		72	4101	
73	4102		74	4103	
75	4115		76	4116	
77	4117		78	4118	
79	4119		80	4120	

81	4121		82	4122	
83	4123		84	4124	
85	4125		86	4126	
87	4127		88	4128	
89	4129		90	4130	
91	4131		92	4132	
93	4137		94	4138	
95	4139		96	4140	

97	4141		98	4142	
99	4143		100	4144	
101	4145		102	4146	
103	4147		104	4149	
105	4150		106	4151	
107	4152		108	4153	
109	4154		110	4155	
111	4156		112	4157	
















					
113	4158		114	4159	
115	4160		116	4161	
117	4162		118	4163	
119	4164		120	4165	
121	4166		122	4167	
123	4168		124	4169	
125	4170		126	4171	
127	4172		128	4173	

















129	4174		130	4175	
131	4176		132	4177	
133	4188		134	4189	
135	4190		136	4191	
137	4192		138	4193	
139	4194		140	4195	
141	4196		142	4197	
143	4198		144	4199	

















145	4200		146	4201	
147	4202		148	4203	
149	4204		150	4205	
151	4206		152	4207	
153	4618		154	4619	
155	4620		156	4621	
157	4625		158	6892	

















8. Spoj derivata 1,3,4-oksadiazola, njegov optički izomer ili njegova farmaceutski prihvatljiva sol prema zahtjevu 7, naznačen time što je bilo koji od spojeva navedenih u sljedećoj tablici:






Prim.	Spoj	Struktura	Prim.	Spoj	Struktura
33	3782		34	3783	
40	4036		75	4115	
76	4116		77	4117	
78	4118		79	4119	
80	4120		81	4121	
82	4122		83	4123	
84	4124		85	4125	
86	4126		87	4127	

					
88	4128		89	4129	
90	4130		91	4131	
92	4132		93	4137	
94	4138		95	4139	
96	4140		97	4141	
98	4142		99	4143	
100	4144		101	4145	
102	4146		103	4147	










					
104	4149		105	4150	
106	4151		107	4152	
108	4153		109	4154	
110	4155		111	4156	
112	4157		113	4158	
114	4159		115	4160	
116	4161		117	4162	
118	4163		119	4164	

					
120	4165		121	4166	
122	4167		123	4168	
124	4169		125	4170	
126	4171		127	4172	
128	4173		129	4174	
130	4175		131	4176	
132	4177		133	4188	
134	4189		135	4190	

					
136	4191		137	4192	
138	4193		139	4194	
140	4195		141	4196	
142	4197		143	4198	
144	4199		145	4200	
146	4201		147	4202	
148	4203		149	4204	
150	4205		151	4206	


					
152	4207		153	4618	
154	4619				

9. Spoj derivata 1,3,4-oksadiazola, njegov optički izomer ili njegova farmaceutski prihvatljiva sol prema zahtjevu 7, naznačen time što je bilo koji od spojeva navedenih u sljedećoj tablici:

Prim.	Spoj	Struktura	Prim.	Spoj	Struktura
35	3784		36	3785	
37	4033		38	4034	
39	4035		41	4037	
42	4038		43	4039	
44	4040		45	4041	










46	4042		47	4043	
48	4044		49	4045	
50	4046		51	4047	
52	4048		53	4049	
54	4083		55	4084	
56	4085		57	4086	
58	4087		59	4088	
60	4089		61	4090	

62	4091		63	4092	
64	4093		65	4094	
66	4095		67	4096	
68	4097		69	4098	
70	4099		71	4100	
72	4101		73	4102	
74	4103		155	4620	
156	4621		157	4625	
158	6892				



10. Spoj derivata 1,3,4-oksadiazola, njegov optički izomer ili njegova farmaceutski prihvatljiva sol prema zahtjevu 7, naznačen time što je bilo koji od spojeva navedenih u sljedećoj tablici:

Prim.	Spoj	Struktura	Prim.	Spoj	Struktura
1	3009		2	3585	
3	3586		4	3587	
5	3588		6	3589	
7	3590		8	3591	
9	3592		10	3593	
11	3594		12	3595	
13	3596		14	3668	
15	3669		16	3670	
17	3671		18	3672	
19	3673		20	3674	
21	3675		22	3676	

23	3677		24	3678	
25	3679		26	3719	
27	3720		28	3721	
29	3722		30	3723	
31	3724		32	3725	

11. Farmaceutski pripravak za upotrebu u prevenciji ili liječenju bolesti posredovanih histon deacetilazom 6, naznačen time što kao aktivni sastojak sadrži spoj predstavljen kemijskom formulom I, njegov optički izomer ili njegovu farmaceutski prihvatljivu sol prema bilo kojem od zahtjeva 1 do 10.
- 5 12. Farmaceutski pripravak za upotrebu u prevenciji ili liječenju bolesti posredovanih histon deacetilazom 6 prema zahtjevu 11, naznačen time što su bolesti posredovane histon deacetilazom 6 zarazne bolesti; neoplazma; endokrine, nutritivne i metaboličke bolesti; mentalni poremećaji i poremećaji ponašanja; neurološke bolesti; bolesti oka i adneksa; bolesti cirkulacije; bolesti dišnog sustava; probavne bolesti; bolesti kože i potkožnog tkiva; bolesti mišićno-koštanog i vezivnog tkiva; ili kongenitalne malformacije, promjene ili kromosomske abnormalnosti.
- 10 13. Spoj derivata 1,3,4-oksadiazola predstavljen kemijskom formulom I, njegov optički izomer ili njegova farmaceutski prihvatljiva sol prema bilo kojem od zahtjeva 1 do 10, za upotrebu u prevenciji ili liječenju bolesti posredovanih histon deacetilazom 6.